Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria

Abstract Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted to assess the hepatic safety of cipargam...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical infectious diseases 2022-05, Vol.74 (10), p.1831-1839
Hauptverfasser:	Schmitt, Esther K, Ndayisaba, Gilles, Yeka, Adoke, Asante, Kwaku Poku, Grobusch, Martin P, Karita, Etienne, Mugerwa, Henry, Asiimwe, Stephen, Oduro, Abraham, Fofana, Bakary, Doumbia, Seydou, Su, Guoqin, Csermak Renner, Katalin, Venishetty, Vinay Kumar, Sayyed, Sarfaraz, Straimer, Judith, Demin, Ivan, Barsainya, Sarita, Boulton, Caroline, Gandhi, Preetam
Format:	Artikel
Sprache:	eng
Schlagworte:	Major and Commentaries
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!